ETF Holdings Breakdown of AGIO

AGIO institutional holdings

The adjusted close for AGIO on 2025-11-13 was 42.54

The following institutional investment holdings of AGIO have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-13	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	39,252	USD 1,669,780	42.54
2025-11-13	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	5,880	USD 250,135	42.54
2025-11-13	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	37,372	USD 1,589,805 -2.6%	42.54
2025-11-13	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	37,372	USD 1,589,805	42.54
2025-11-13	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	134	USD 5,700	42.54
Total =		120,010	USD 5,105,225

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with AGIO

AGIO Crosses Below Key Moving Average Level

In trading on Thursday, shares of Agios Pharmaceuticals Inc (Symbol: AGIO) crossed below their 200 day moving average of $35.78, changing hands as low as $32.70 per share. Agios Pharmaceuticals Inc shares are currently trading down about 14.2% on the day. The chart below shows - 2025-09-04 12:41:27

Deutsche Bank AG Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Deutsche Bank AG decreased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 0.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 928,970 shares of the biopharmaceutical company’s stock after selling 6,282 shares during the quarter. Deutsche Bank AG’s […] - 2025-08-13 05:20:52

Agios Pharmaceuticals Becomes Oversold (AGIO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me - 2025-08-04 12:58:40

Agios Pharmaceuticals (AGIO) Shares Cross Below 200 DMA

In trading on Thursday, shares of Agios Pharmaceuticals Inc (Symbol: AGIO) crossed below their 200 day moving average of $36.97, changing hands as low as $35.81 per share. Agios Pharmaceuticals Inc shares are currently trading down about 0.6% on the day. The chart below shows - 2025-07-31 14:21:35

Bullish Two Hundred Day Moving Average Cross - AGIO

In trading on Wednesday, shares of Agios Pharmaceuticals Inc (Symbol: AGIO) crossed above their 200 day moving average of $37.36, changing hands as high as $38.82 per share. Agios Pharmaceuticals Inc shares are currently trading up about 6.6% on the day. The chart below shows - 2025-07-09 12:42:52

Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $58.60

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month […] - 2025-07-02 03:14:49

Agios' PYRUKYND Faces FDA Review In September - Expansion Opportunity Ahead?

(RTTNews) - Shares of Agios Pharmaceuticals Inc. (AGIO) have retreated approximately 43% from their 52-week high of $62.58, reported last November, and trade near the $35 level. - 2025-06-17 08:36:03

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 9,606 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 8.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 122,835 shares of the biopharmaceutical company’s stock after acquiring an additional 9,606 shares during […] - 2025-06-05 05:13:00

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of “Moderate Buy” by Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price […] - 2025-06-04 04:52:50

Two Sigma Advisers LP Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Two Sigma Advisers LP acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 22,200 shares of the biopharmaceutical company’s stock, valued at approximately $729,000. A number of other […] - 2025-06-03 04:56:54

Two Sigma Investments LP Makes New $3.59 Million Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Two Sigma Investments LP purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 109,373 shares of the biopharmaceutical company’s stock, valued at approximately $3,594,000. A number of other hedge funds and other institutional investors have also bought and sold shares of AGIO. Jefferies […] - 2025-05-30 05:24:59

BNP Paribas Financial Markets Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

BNP Paribas Financial Markets decreased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 18.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,704 shares of the biopharmaceutical company’s stock after selling 2,242 shares during the quarter. BNP Paribas Financial […] - 2025-05-27 04:38:56

Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to Sell at StockNews.com

StockNews.com downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a hold rating to a sell rating in a research report released on Monday morning. Several other brokerages also recently commented on AGIO. Scotiabank reduced their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company […] - 2025-05-20 02:36:56

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Position Reduced by Voya Investment Management LLC

Voya Investment Management LLC cut its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 48.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 33,007 shares of the biopharmaceutical company’s stock after selling 30,733 shares during the period. Voya Investment Management LLC’s holdings in Agios Pharmaceuticals were worth $1,085,000 as of its […] - 2025-05-07 06:32:51

Scotiabank Cuts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $71.00

Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) had its price objective lowered by Scotiabank from $74.00 to $71.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a sector outperform rating on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on AGIO. HC Wainwright assumed coverage on […] - 2025-05-05 04:38:49

CANADA LIFE ASSURANCE Co Sells 1,094 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

CANADA LIFE ASSURANCE Co reduced its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 5.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 18,979 shares of the biopharmaceutical company’s stock after selling 1,094 shares during the period. CANADA LIFE ASSURANCE […] - 2025-04-30 05:48:58

Invesco Ltd. Sells 35,432 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Invesco Ltd. reduced its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 29.8% in the fourth quarter, HoldingsChannel reports. The firm owned 83,515 shares of the biopharmaceutical company’s stock after selling 35,432 shares during the quarter. Invesco Ltd.’s holdings in Agios Pharmaceuticals were worth $2,744,000 as of its most recent filing […] - 2025-04-29 04:25:06

Barclays PLC Sells 90,864 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Barclays PLC lowered its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 42.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 121,753 shares of the biopharmaceutical company’s stock after selling 90,864 shares during the quarter. Barclays PLC owned approximately 0.21% […] - 2025-04-28 05:01:17

Legal & General Group Plc Sells 1,424 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Legal & General Group Plc lessened its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 1.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 71,677 shares of the biopharmaceutical company’s stock after selling 1,424 shares during the quarter. Legal & General Group Plc’s holdings in Agios Pharmaceuticals were worth $2,355,000 […] - 2025-04-25 05:08:57

Federated Hermes Inc. Purchases 582 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Federated Hermes Inc. lifted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,691 shares of the biopharmaceutical company’s stock after buying an additional 582 shares during the period. Federated […] - 2025-04-18 04:53:04

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.57 Consensus PT from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month […] - 2025-04-18 02:28:57

Norges Bank Takes $4.77 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Norges Bank purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 145,092 shares of the biopharmaceutical company’s stock, valued at approximately $4,768,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AGIO. NEOS Investment […] - 2025-04-10 05:02:57

Vanguard Group Inc. Grows Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Vanguard Group Inc. raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 1.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,631,321 shares of the biopharmaceutical company’s stock after buying an additional 85,339 shares during the […] - 2025-04-07 05:06:53

Thrivent Financial for Lutherans Sells 7,077 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Thrivent Financial for Lutherans decreased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 28.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 17,526 shares of the biopharmaceutical company’s stock after selling 7,077 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Agios Pharmaceuticals were worth $576,000 at the end of […] - 2025-04-04 04:32:55

Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) PT at $56.57

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target […] - 2025-03-26 04:57:01

Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Decreases By 14.9%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 3,940,000 shares, a drop of 14.9% from the February 13th total of 4,630,000 shares. Based on an average daily volume of 895,400 shares, […] - 2025-03-21 04:26:52

AlphaQuest LLC Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

AlphaQuest LLC raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 106.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,540 shares of the biopharmaceutical company’s stock after buying an additional 2,338 shares during the quarter. AlphaQuest […] - 2025-03-18 06:03:33

New York State Common Retirement Fund Purchases 4,663 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

New York State Common Retirement Fund boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 13.5% in the fourth quarter, Holdings Channel reports. The fund owned 39,093 shares of the biopharmaceutical company’s stock after purchasing an additional 4,663 shares during the quarter. New York State Common Retirement Fund’s holdings in […] - 2025-03-03 07:20:48

Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at StockNews.com

StockNews.com lowered shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a hold rating to a sell rating in a research note issued to investors on Friday morning. A number of other research firms have also recently commented on AGIO. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report […] - 2025-02-17 04:53:15

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by KBC Group NV

KBC Group NV lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 30.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,615 shares of the biopharmaceutical company’s stock after buying an additional 611 shares during the quarter. KBC Group NV’s holdings […] - 2025-02-10 16:27:00

Back to Listing

Disclaimer